Earnings Beat, Increased FY22 Outlook, Rising Biosimilar Competition: Biogen's Q2 Highlights

  • Biogen Inc BIIB has posted Q2 sales of $2.59 billion, beating the consensus of $2.48 billion, down 7% Y/Y and 5% at constant currency (CC).
  • Multiple sclerosis revenue, including royalties on sales of Ocrevus, of $1.72 billion decreased by 4% (down 3% CC).
  • Spinraza's revenue of $431 million decreased by 14% at actual currency (by 11% at CC).
  • Aduhelm generated sales of a mere $0.1 million in Q2.
  • Biosimilars' revenue of $194 million decreased 4% versus the prior year at actual currency and increased 3% at constant currency.
  • Multiple sclerosis drug Tysabri sales are down 1.5% to $516.2 million.
  • Adjusted EPS of $5.25 was down from $5.58 a year ago, beating the consensus of $4.10.
  • Guidance: Biogen raised FY22 sales guidance to $9.9 billion - $10.1 billion, up from $9.7 billion - $10 billion versus the consensus of $9.84 billion.
  • The company expects adjusted EPS of $15.25-$16.75, up from $14.25-$16.00 compared to the consensus of $15.54.
  • The increase in guidance is driven primarily by better-than-expected topline performance and continued cost management.
  • Price Action: BIIB shares are down 0.24% at $219.74 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!